Pacira BioSciences Inc

NASDAQ:PCRX   11:18:09 AM EDT
53.85
+1.01 (+1.91%)
Products, Regulatory

Pacira Biosciences Announces Positive Topline Data From Phase 3 Study Of Exparel As A Single-Dose Sciatic Nerve Block In The Popliteal Fossa For Bunionectomy

Published: 09/21/2022 12:54 GMT
Pacira BioSciences Inc (PCRX) - Pacira Biosciences Announces Positive Topline Data From Phase 3 Study of Exparel As a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy.
Pacira Biosciences Inc - Company on Track to Submit Supplemental New Drug Application in Q1 of 2023.
Pacira Biosciences Inc - Exparel Was Well Tolerated With a Safety Profile Consistent With Bupivacaine Hcl.
Pacira Biosciences Inc - Plans to Submit a Snda to U.S. Food and Drug Administration (fda) Early Next Year to Expand Exparel Label.